Sector News

Transgene is shedding 120 jobs to save cash and get its pipeline moving

June 30, 2015
Life sciences
French biotech Transgene is planning to slash its payroll and redouble its focus on clinical development, moving on from a costly snub at the hands of Novartis.
 
The company will let go of about 120 employees as it steps away from vertical integration, cutting its losses in development and manufacturing with the goal of leaning on contractors to fill the void. With the resulting savings, Transgene plans to focus on R&D, investing in its pipeline of mid-stage treatments and laying out funds for translational research, the company said.
 
Transgene is also using the opportunity to rethink its approach to developing drugs, according to management, looking more to collaborations with academia and biopharma partners and vowing to consider deals at earlier stages of the process.
 
The change, which sent Transgene’s shares down about 14%, comes about a year after ex-partner Novartis decided against opting in on TG4010, a Phase II vaccine targeting lung cancer. The Swiss drugmaker’s decision nixed an agreement worth as much as $800 million, deflating Transgene’s market value in the process. The biotech has since promised to go it alone on a Phase III trial for TG4010 but is yet to begin enrollment.
 
Transgene has stressed that it will do everything it can to find new jobs for the employees affected by its latest cuts, working with top shareholder Institut Mérieux to place them. The company is “committed to by all means minimizing as much as possible the social impact of the restructuring plan,” management said in a statement, and the goal “is to leave no one without a solution.”
 
Meanwhile, Transgene and partner SillaJen are blueprinting a Phase III trial for Pexa-Vec, a vaccine for liver cancer that missed its main goal in Phase IIb. The partners got the FDA’s sign-off on their proposed study design in April and plan to enroll about 600 patients later this year. Transgene is also at work on earlier stage therapies for HPV-induced cancers, solid tumors, hepatitis B and tuberculosis.
 
By Damian Garde
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach